Ellis Christopher's Form 4 filing
Barinthus Biotherapeutics plc. (BRNS) · filed Jul 15, 2022
- Accession no.
- 0001104659-22-080209
- Filed
- Jul 15, 2022
- Trade date
- Jun 28, 2022
- Filing delay
- 17 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $30. It was filed 17 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ellis ChristopherCIK 0001851664 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 28, 2022 | Ordinary Shares | MOption exerciseAcquired | +5 | $0.00 | $0 | 80 | Direct | |
| Jun 28, 2022 | Ordinary Shares | SSaleDisposed | −5 | $6.00 | −$30 | 75 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 28, 2022 | Ordinary Shares | MOption exerciseDisposed | −5 | $0.00 | $0 | 50,980 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.